ArticleJournal of autoimmunity2020
TIGIT
Article in Journal of autoimmunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Regulatory T cell dysfunction and exhaustion in uveitis: immunometabolic mechanisms, microenvironmental drivers, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites.Molecular biology reports · 2025Review
- Purin Metabolism Is Crucial for Regulatory T Cell Stability and Function.European journal of immunology · 2025Review
- CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis.Scientific reports · 2025Article
- Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.Frontiers in immunology · 2025Review
- TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration.Journal of leukocyte biology · 2024Article
- Decreased expression of TIGIT on CD14 + monocytes correlates with clinical features and laboratory parameters of patients with primary Sjögren's syndrome.Clinical rheumatology · 2024Article
- A2Ar-dependent PD-1+ and TIGIT+ Treg cells have distinct homing requirements to suppress autoimmune uveitis in mice.Mucosal immunology · 2023Article
- Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.Advanced drug delivery reviews · 2023Review
- TIGIT axis: novel immune checkpoints in anti-leukemia immunity.Clinical and experimental medicine · 2023Review
- Long-lived autoreactive memory CD4FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment.Frontiers in oncology · 2023Review
- Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses.Cell reports · 2022Article
- Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy.Frontiers in immunology · 2022Review
- Regulatory T Cells: Therapeutic Opportunities in Uveitis.Frontiers in ophthalmology · 2022Review
- TIGIT as a Promising Therapeutic Target in Autoimmune Diseases.Frontiers in immunology · 2022Review
- CD4International journal of molecular sciences · 2021Review
- Combined Deficiency of the Melanocortin 5 Receptor and Adenosine 2A Receptor Unexpectedly Provides Resistance to Autoimmune Disease in a CD8Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Regulatory T cells (Tregs) are necessary to prevent autoimmune disease. As such, stable FoxP3 expression is required for the proper function of Tregs in the control of autoimmune disease. Different Treg subsets that utilize different mechanisms of suppression have been identified. The T-cell immunoglobulin immunoreceptor tyrosine-based inhibitory motif (TIGIT) is a relatively new Treg cell marker that has a suppressive function. We have previously identified the adenosine 2A receptor (A2Ar) as a requirement for the emergence of Tregs following resolution of autoimmune disease. Using a FoxP3-GFP-Cre reporter mouse, we identify FoxP3 and 'exFoxP3' cells, show FoxP3 and not exFoxP3 cells are suppressive. We further show FoxP3 cells express TIGIT, and are induced through A2Ar in healthy volunteers, but not patients with autoimmune disease. Furthermore, we show Tregs emerge in the target tissue at the onset of autoimmune disease in an A2Ar-dependent manner. In summary, we identify a novel subset of TIGIT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.